CollPlant Biotechnologies Ltd.
CLGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $515 | $10,959 | $299 | $15,641 |
| % Growth | -95.3% | 3,565.2% | -98.1% | – |
| Cost of Goods Sold | $2,663 | $3,093 | $1,476 | $2,005 |
| Gross Profit | -$2,148 | $7,866 | -$1,177 | $13,636 |
| % Margin | -417.1% | 71.8% | -393.6% | 87.2% |
| R&D Expenses | $10,515 | $10,484 | $10,255 | $7,631 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $4,588 | $4,894 | $5,665 | $5,940 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15,103 | $15,378 | $15,920 | $13,571 |
| Operating Income | -$17,251 | -$7,512 | -$17,097 | $65 |
| % Margin | -3,349.7% | -68.5% | -5,718.1% | 0.4% |
| Other Income/Exp. Net | $642 | $493 | $172 | $172 |
| Pre-Tax Income | -$16,609 | -$7,019 | -$16,925 | $237 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16,609 | -$7,019 | -$16,925 | $237 |
| % Margin | -3,225% | -64% | -5,660.5% | 1.5% |
| EPS | -1.45 | -0.62 | -1.52 | 0.041 |
| % Growth | -133.9% | 59.2% | -3,807.3% | – |
| EPS Diluted | -1.45 | -0.62 | -1.52 | 0.034 |
| Weighted Avg Shares Out | 11,454 | 11,389 | 11,033 | 9,969 |
| Weighted Avg Shares Out Dil | 11,454 | 11,389 | 11,033 | 11,967 |
| Supplemental Information | – | – | – | – |
| Interest Income | $738 | $788 | $321 | $219 |
| Interest Expense | $17 | $10 | $34 | $37 |
| Depreciation & Amortization | $1,038 | $1,102 | $1,076 | $773 |
| EBITDA | -$15,554 | -$5,907 | -$15,815 | $1,047 |
| % Margin | -3,020.2% | -53.9% | -5,289.3% | 6.7% |